The Spinal Muscular Atrophy (SMA) drugs in development market research report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Spinal Muscular Atrophy (SMA). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued products.

GlobalData tracks 52 drugs in development for Spinal Muscular Atrophy (SMA) by 46 companies/universities/institutes. The top development phase for Spinal Muscular Atrophy (SMA) is preclinical with 23 drugs in that stage. The Spinal Muscular Atrophy (SMA) pipeline has 40 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Spinal Muscular Atrophy (SMA) pipeline products market are: Biogen, Oncternal Therapeutics and Apteeus.

The key targets in the Spinal Muscular Atrophy (SMA) pipeline products market include Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2), Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN), and Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR).

The key mechanisms of action in the Spinal Muscular Atrophy (SMA) pipeline product include Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Activator with 18 drugs in Phase III. The Spinal Muscular Atrophy (SMA) pipeline products include seven routes of administration with the top ROA being Oral and eight key molecule types in the Spinal Muscular Atrophy (SMA) pipeline products market including Small Molecule, and Gene Therapy.

Spinal Muscular Atrophy (SMA) overview

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

For a complete picture of Spinal Muscular Atrophy (SMA)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.